Symptoms of COVID-19 and influenza may look similar1. Providing access to reliable and efficient testing on the fully-automated cobas® 6800/8800 Systems can help guide treatment decisions and prevent further disease transmission.
Both SARS-CoV-2 and influenza infections can present with similar symptoms, but treatment directions are likely to be different1. Knowing what infection a patient has will allow the clinician to optimally guide triage and treatment decisions, and bring confidence to patients.
The cobas® SARS-CoV-2 & Influenza A/B Test is a multiplex reverse transcription polymerase chain reaction (RT-PCR) assay intended for simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus in nasal or nasopharyngeal swab samples collected from individuals suspected of a respiratory viral infection consistent with COVID-19 by their healthcare provider.
Provide accurate diagnosis of SARS-CoV-2 or Influenza A/B infection for proper patient management.
Offer reliable and affordable testing to reduce further virus spreading after close contact with infected individuals.
Leverage high-volume cobas® 6800/8800 Systems and broad menu to expand COVID-19 testing solutions.
FDA-Emergency Use Authorization, CE-IVD
In the United States:
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A virus, and influenza B virus, and not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Related Products
Test Performance
Se hela tabellenTest Performance
| TARGET | POSITIVE AGREEMENT | NEGATIVE AGREEMENT | LoD (95% Probit)c |
| SARS-CoV-2* | 96.4%a | 98.0%a | 0.0063 TCID50/mL (SARS-CoV-2)b 0.0082 TCID50/mL (pan-Sarbecovirus)b |
| Influenza A** | 100% | 99.6% | 0.086 TCID50/mL |
| Influenza B** | 100% | 99.7% | 0.026 TCID50/mL |
* compared to FDA-cleared EUA, cobas® SARS-CoV-2 Test on cobas® 6800/8800 Systems
** compared to FDA-cleared multiplexed real-time reverse transcriptase PCR (RT-PCR) test
a discordant results for SARS-CoV-2 are from samples of recovery/convalescent patients with decreasing viral loads close to or below the LOD of both tests
b one TCID50/mL is equal to 7,393 genome equivalents by ddPCR (per vendor’s Certificate of Analysis, USA-WA1/2020, infectious culture, Cat No NR-52281, Lot 70033175)
c based on co-formulated, combined lot performance
Key Parameters
Se hela tabellenKey Parameters
| PARAMETER | PERFORMANCE |
| Targets | SARS-CoV-2, pan-Sarbecovirus, Influenza A, Influenza B |
| Sample type |
Nasopharyngeal swab samples collected in the Copan UTM-RT System or the BD UVT System Nasal swab samples collected in the Copan UTM-RT System, the BD UVT System, the cobas® PCR media, and 0.9% physiological saline |
| Minimum amount of sample required | 0.6 µL |
| Sample processing volume | 0.4 µL |
| Test duration | Results are available within less than 3.5 hours after loading the sample on the system |
| System software | Runs with SW versions 1.2, 1.3, and 1.4 |
| Size and open kit stability | 384 tests; 90 days with 40 re-uses |
